These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 19450080

  • 21. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 22. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF.
    J Support Oncol; 2005 Apr; 3(6):419-26. PubMed ID: 16350429
    [Abstract] [Full Text] [Related]

  • 23. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A, Edelsberg J, Kallich J, Oster G.
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [Abstract] [Full Text] [Related]

  • 24. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Jan; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 25. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J, Reeves T, Wallace J.
    Oncologist; 2004 May; 9(4):451-8. PubMed ID: 15266098
    [Abstract] [Full Text] [Related]

  • 27. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 28. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, Van Belle S.
    Clin Ther; 2014 Apr 01; 36(4):594-610. PubMed ID: 24656152
    [Abstract] [Full Text] [Related]

  • 29. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Apr 01; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 30. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A, Yee J, Gandra SR, Khan I, Petersen J.
    Curr Med Res Opin; 2010 Nov 01; 26(11):2679-87. PubMed ID: 20942616
    [Abstract] [Full Text] [Related]

  • 31. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 01; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 32. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J.
    Oncology (Williston Park); 2006 Jul 01; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [Abstract] [Full Text] [Related]

  • 33. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec 01; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 34. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.
    Raymond CB, Wazny LD, Vercaigne LM, Lesperance EM, Skwarchuk DE, Bernstein KN.
    CANNT J; 2008 Dec 01; 18(1):39-43. PubMed ID: 18435363
    [Abstract] [Full Text] [Related]

  • 35. Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy.
    McGarvey N, Xu H.
    J Health Econ Outcomes Res; 2016 Dec 01; 3(2):214-223. PubMed ID: 37663317
    [Abstract] [Full Text] [Related]

  • 36. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 01; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 37. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.
    Clin Ther; 2006 Sep 01; 28(9):1443-50. PubMed ID: 17062316
    [Abstract] [Full Text] [Related]

  • 38. Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia.
    Muller RJ, Baribeault D.
    Am J Health Syst Pharm; 2007 Dec 15; 64(24):2547-56. PubMed ID: 18056942
    [Abstract] [Full Text] [Related]

  • 39. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
    Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.
    Drugs Aging; 2006 Dec 15; 23(12):969-76. PubMed ID: 17154661
    [Abstract] [Full Text] [Related]

  • 40. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.
    Eur Heart J; 2007 Sep 15; 28(18):2208-16. PubMed ID: 17681958
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.